Just caught up on Caribou's earnings from a few months back and honestly the numbers were pretty solid. They posted a quarterly loss of 28 cents per share, which beat expectations by beating out the consensus estimate of 33 cents loss. Revenue hit 3.94 million and crushed the estimate by over 56%, so that's definitely the highlight here. Year-over-year the revenue more than doubled from 2.08 million, which is a pretty strong move for a biotech company. The stock has been up around 13% since the start of the year while the broader market barely moved, so Caribou investors have had a decent ride so far. What's interesting is that Caribou has been consistently beating on the earnings side - they've topped EPS estimates three times in the last four quarters. That kind of track record tends to matter when you're looking at where a stock goes next. The real question now is whether they can keep this momentum. The consensus estimates are calling for continued losses in the near term, which is pretty normal for biotech, but the revenue growth trajectory is what people are watching. One thing to keep an eye on though - the Medical Biomedical and Genetics industry as a whole is in the bottom 46% of performance rankings, so even when individual companies like Caribou do well, sector headwinds can still be a factor. If you're thinking about biotech plays, Caribou's recent execution has been solid, but always worth checking where management thinks they're headed on the next call.